MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment

著录项

• 来源
  《细胞与分子免疫学：英文版》 |2016年第5期|P.658-668|共11页
• 作者

  Hua He15; Maojin Yao25; Wenhao Zhang35; Bangbao Tao45; Feili Liu4; Shu Li5; Yan Dong1; Chenran Zhang1; Yicheng Meng1; Yuxin Li1; Guohan Hu1; Chun Luo1; Hui Zong2; Yicheng Lu1;

  展开▼
• 作者单位

  [1]Department of Neurosurgery Changzheng Hospital Second Affiliated Hospital of Second Military Medical University 415 Fengyang Road Shanghai 200003 P.R.China;

  [2]Department of Microbiology Immunology and Cancer Biology School of Medicine University of Virginia USA;

  [3]Department of Hematology Xinhua Hospital School of Medicine Shanghai Jiaotong University Shanghai China;

  [4]Department of Neurosurgery Xinhua Hospital School of Medicine Shanghai Jiaetong University Shanghai China;

  [5]Department of Pathophysiology Wannan Medical College 22 Wenchang Road Wuhu 241002 China;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 chi
• 中图分类 基因的表达;
• 关键词

  胶质瘤细胞; 化疗药物; 替莫唑胺; 增敏剂; 治疗; 预后; 丝裂原活化蛋白激酶; 患者;

  机译：胶质瘤细胞;化疗药物;替莫唑胺;增敏剂;治疗;预后;丝裂原活化蛋白激酶;患者;